Comparative Pharmacology
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE.
BETAXOLOL HYDROCHLORIDE vs DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces aqueous humor production by blocking beta-2 adrenergic receptors in the ciliary epithelium.
10-20 mg orally once daily; maximum 20 mg/day.
One drop of the fixed combination (dorzolamide 22.26 mg/mL, timolol 6.83 mg/mL) in the affected eye(s) every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
Dorzolamide: ~4 months but accumulates in RBCs; terminal half-life ~4-5 months due to binding to carbonic anhydrase. Timolol: ~4-6 hours.
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Dorzolamide: primarily renal (approx. 80% unchanged), with minor biliary/fecal elimination. Timolol: renal (15-20% unchanged) and extensive hepatic metabolism with fecal excretion.
Category C
Category A/B
Beta-Blocker
Beta-Blocker